The eNose Company

The eNose Company's mission is to transform diagnostics through its portable, non-invasive Aeonose™ technology, which analyzes breath to detect diseases like lung cancer and tuberculosis within minutes. Key achievements include CE-marking for its device, multiple published clinical studies, and a public listing to fund commercialization. Its strategy is to validate its platform across multiple high-burden indications, securing regulatory approvals and building partnerships for global deployment in screening and triage settings.

The Aeonose™ is a handheld electronic nose that uses an array of metal-oxide semiconductor sensors and proprietary machine learning algorithms to analyze volatile organic compound (VOC) patterns in exhaled breath for non-invasive disease detection and monitoring.

The company competes with other breath analysis firms like Owlstone Medical, as well as alternative non-invasive diagnostic methods such as liquid biopsies. Its differentiation is based on the point-of-care design of its Aeonose™ device and its advanced clinical validation in specific high-burden diseases.